Evaxion announces promising clinical data for dna-based personalized cancer immunotherapy evx-02: phase 1/2a trial met both primary and secondary endpoints

Copenhagen, denmark, april 18, 2023 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the development of ai-powered immunotherapies, today presented promising clinical data from its phase 1/2a first-in-human study of its dna-based personalized cancer immunotherapy, evx-02 in combination with the checkpoint inhibitor nivolumab. data were presented in the late breaking research: clinical research 2 session at the 2023 aacr (american association for cancer research) meeting in orlando, florida.
EVAX Ratings Summary
EVAX Quant Ranking